bladder cancer

  • September 16, 2024  

    How an Expert Would Manage His Own Advanced Bladder Cancer: An Update

    With: Daniel E.C. Fein, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Daniel E.C. Fein, MD, how he would handle his own case of advanced bladder cancer. Dr. Fein is a genitourinary oncologist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA, as well as an Instructor in Medicine… Read more »

  • November 21, 2023  

    High-Energy Blue Light Powers a Promising New Treatment to Destroy Cancer Cells

    With: Stuart L. Marcus, MD, PhD

    A perennial challenge in cancer treatment is figuring out how to kill tumor cells while leaving healthy cells unharmed. Our Curious Dr. George asks Stuart L. Marcus, MD, PhD, founder and Chief Science Officer at SonALAsense, how his company’s light-activated drug treatment addresses this challenge, holding potential promise for people with brain, bladder, and possibly other cancers. Curious Dr. George: Your flagship treatment employs… Read more »

  • May 20, 2023  

    How Would an Expert Manage His Own Advanced Bladder Cancer?

    With: Daniel E.C. Fein, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Daniel E.C. Fein, MD, how he would handle his own case of advanced bladder cancer. Dr. Fein is a genitourinary oncologist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA, as well as an Instructor in Medicine… Read more »

  • December 13, 2019  

    Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections Bookmark

    George Lundberg, MD

    Research paper from the Archives of Pathology & Laboratory Medicine curated by Editor in Chief George Lundberg, MD, who notes: 

    Plasmacytoid urothelial carcinoma merits special aggressive therapy.

    Go to full paper published in the Archives of Pathology & Laboratory Medicine.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 13, 2019  

    Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Based Therapy (RANGE): Overall Survival and Updated Results of a Randomised, Double-Blind, Phase 3 Trial Bookmark

    George Lundberg, MD

    Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

    A drug called Cyramza improves progession-free survival (PFS) but not overall survival (OS) of patients with advanced bladder cancer in a phase lll clinical trial.

    Go to full paper published in The Lancet.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 15, 2019  

    Bladder Cancer—A Comprehensive Overview Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Cancer of the urinary bladder is common, commonly recurs, and can be fatal. To learn more, read this up-to-date, comprehensive, unbiased, and balanced report from Medscape.